Evaxion announces 2025 milestones reflecting continued strong strategy execution
Evaxion Biotech (NASDAQ: EVAX) has announced its strategic milestones for 2025 following the successful achievement of most 2024 goals. The company's key priorities include executing business development strategy, continuing the EVX-01 phase 2 trial, strengthening their AI-Immunology™ platform, and advancing research activities.
The 2025 milestones include: launching an automated lead vaccine candidate design module in H2, securing at least two new partnership agreements, completing EVX-01 patient dosing in H1, obtaining phase 2 clinical efficacy readout in H2, selecting a lead vaccine candidate for precision ERV cancer vaccines, potential MSD option exercise worth up to $10 million, selecting lead antigens for CMV vaccine candidate, and introducing two new pipeline candidates in infectious diseases.
Evaxion Biotech (NASDAQ: EVAX) ha annunciato i suoi obiettivi strategici per il 2025, dopo aver raggiunto con successo la maggior parte degli obiettivi per il 2024. Le principali priorità dell'azienda includono l'esecuzione della strategia di sviluppo commerciale, il proseguimento del trial di fase 2 EVX-01, il rafforzamento della loro piattaforma AI-Immunology™ e l'avanzamento delle attività di ricerca.
Gli obiettivi per il 2025 includono: il lancio di un modulo automatizzato per la progettazione di candidati vaccinali nel secondo semestre, la conclusione di almeno due nuovi accordi di collaborazione, il completamento della somministrazione del farmaco EVX-01 ai pazienti nel primo semestre, l'ottenimento di risultati clinici di efficacia della fase 2 nel secondo semestre, la selezione di un candidato vaccinale principale per i vaccini contro il cancro ERV di precisione, l'esercizio di un'opzione potenziale MSD del valore di fino a 10 milioni di dollari, la selezione di antigeni principali per il candidato vaccinale CMV e l'introduzione di due nuovi candidati nella pipeline relative a malattie infettive.
Evaxion Biotech (NASDAQ: EVAX) ha anunciado sus objetivos estratégicos para 2025 tras haber alcanzado con éxito la mayoría de los objetivos de 2024. Las prioridades clave de la empresa incluyen la ejecución de la estrategia de desarrollo comercial, continuar con el ensayo de fase 2 EVX-01, fortalecer su plataforma AI-Immunology™ y avanzar en las actividades de investigación.
Los hitos para 2025 incluyen: lanzar un módulo automatizado para el diseño de candidatos a vacunas en el segundo semestre, asegurar al menos dos nuevos acuerdos de colaboración, completar la administración de pacientes de EVX-01 en el primer semestre, obtener resultados de eficacia clínica de fase 2 en el segundo semestre, seleccionar un candidato de vacuna principal para vacunas contra el cáncer ERV de precisión, un posible ejercicio de opción MSD por un valor de hasta 10 millones de dólares, seleccionar antígenos líderes para el candidato a vacuna CMV e introducir dos nuevos candidatos en la línea de desarrollo de enfermedades infecciosas.
Evaxion Biotech (NASDAQ: EVAX)는 2024년 목표의 대부분을 성공적으로 달성한 후 2025년 전략적 마일스톤을 발표했습니다. 회사의 주요 우선 사항은 사업 개발 전략을 실행하고, EVX-01 2상 시험을 계속하며, AI-Immunology™ 플랫폼을 강화하고, 연구 활동을 진행하는 것입니다.
2025년 마일스톤은 다음과 같습니다: 하반기에 자동화된 백신 후보 설계 모듈 출시, 최소 두 개의 새로운 파트너십 계약 확보, 상반기 EVX-01 환자 투여 완료, 하반기에 2상 임상 효능 데이터 확보, 정밀 ERV 암 백신 후보 선택, 최대 1천만 달러 가치의 MSD 옵션 행사 가능성, CMV 백신 후보를 위한 주요 항원 선택, 전염병에 대한 두 개의 새로운 파이프라인 후보 도입.
Evaxion Biotech (NASDAQ: EVAX) a annoncé ses objectifs stratégiques pour 2025 après avoir atteint avec succès la plupart des objectifs de 2024. Les priorités clés de l'entreprise incluent l'exécution de la stratégie de développement commercial, la poursuite de l'
Les objectifs pour 2025 incluent : le lancement d'un module automatisé de conception de candidats vaccinaux dans la deuxième moitié de l'année, la conclusion d'au moins deux nouveaux accords de partenariat, l'achèvement de la phase de dosage auprès des patients EVX-01 au premier semestre, l'obtention des résultats cliniques d'efficacité de la phase 2 au second semestre, la sélection d'un candidat vaccinal principal pour des vaccins anticancéreux ERV de précision, un exercice d'option MSD potentiel d'une valeur allant jusqu'à 10 millions de dollars, la sélection d'antigènes principaux pour le candidat vaccin CMV et l'introduction de deux nouveaux candidats dans le pipeline des maladies infectieuses.
Evaxion Biotech (NASDAQ: EVAX) hat seine strategischen Meilensteine für 2025 bekannt gegeben, nachdem die meisten Ziele für 2024 erfolgreich erreicht wurden. Die wichtigsten Prioritäten des Unternehmens umfassen die Umsetzung der Geschäftsentwicklungsstrategie, die Fortsetzung der EVX-01 Phase 2 Studie, die Stärkung ihrer AI-Immunologie™-Plattform und die Weiterentwicklung der Forschungsaktivitäten.
Die Meilensteine für 2025 umfassen: den Launch eines automatisierten Moduls zur Gestaltung von Impfstoffkandidaten im zweiten Halbjahr, die Sicherung von mindestens zwei neuen Partnerschaftsvereinbarungen, den Abschluss der EVX-01-Patientendosierung im ersten Halbjahr, die Erlangung von klinischen Wirkungsergebnissen der Phase 2 im zweiten Halbjahr, die Auswahl eines führenden Impfstoffkandidaten für präzise ERV-Krebsimpfstoffe, die Möglichkeit zur Ausübung einer MSD-Option im Wert von bis zu 10 Millionen Dollar, die Auswahl führender Antigene für den CMV-Impfstoffkandidaten und die Einführung von zwei neuen Pipeline-Kandidaten in den Bereich Infektionskrankheiten.
- Potential revenue of up to $10 million from MSD option exercise in H2 2025
- Pipeline expansion with two new infectious disease candidates planned
- Progress in multiple clinical programs including EVX-01 Phase 2 trial
- Strategic partnership opportunities with at least two new agreements targeted
- None.
Insights
This announcement of 2025 milestones lacks material financial details or immediate business impact to warrant significant investor attention. While the company mentions potential milestone payments (up to
- With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025
- The 2025 key milestones reflect all parts of Evaxion’s strategy for value realization
- Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025
COPENHAGEN, Denmark, December 9, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its strategic milestones for 2025 after having now achieved almost all the milestones set for 2024.
The 2025 milestones reflect Evaxion’s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology™ platform and pipeline assets. As such, the milestones underscore our continued anticipated strategic progress.
“We have been very successful in executing our strategy and plans throughout 2024. This makes us excited and confident looking into 2025, as reflected in the milestones for the year. In essence, our strategy for value creation is unchanged and so is our daily focus on executing this strategy to the benefit of shareholders, patients and employees,” says Christian Kanstrup, CEO of Evaxion.
Evaxion’s overriding priorities are execution upon our business development strategy, continuation of the ongoing EVX-01 phase 2 trial, the ongoing strengthening of our AI-Immunology™ platform and further advancement of our research activities, including progressing our ERV-based precision vaccine concept towards clinical development. Finally, the focus is, of course, on advancing our existing partnerships, including bringing the MSD collaboration, entered in September 2024, to option exercise.
All this is reflected in the 2025 milestones as listed below. Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025.
| Milestones | Target | |
| AI-Immunology™ | Launch of automated lead vaccine candidate design module | H2 |
| Business development and partnerships | At least two new agreements | 2025 |
| EVX-01 | All patients completed EVX-01 dosing | H1 |
| EVX-01 | Supplemental phase 2 biomarker and immunogenicity data | H1 |
| EVX-01 | Two-year phase 2 clinical efficacy readout | H2 |
| Precision ERV cancer vaccines | Selection of lead vaccine candidate | H2 |
| MSD vaccine collaboration (EVX-B2/EVX-B3) | MSD option exercise, up to USD 10 million option exercise fee | H2 |
| EVX-V1 | Lead antigens selected for CMV vaccine candidate | H2 |
| Infectious diseases | Two new pipeline candidates | 1 in H1, 1 in H2 |
Contact information
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion-biotech.com
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
What are Evaxion's (EVAX) key milestones for 2025?
What is the potential value of the MSD option exercise for Evaxion (EVAX) in 2025?
When will Evaxion (EVAX) complete EVX-01 patient dosing in Phase 2?
